Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Enveda raised a $311 million Series E at a $2 billion valuation to advance AI-discovered, nature-derived drugs into trials.
Enveda raised a $311 million Series E at a $2 billion valuation to advance nature-derived drugs discovered with AI. Catalio Capital Management led the round, with Iconiq and others participating, doubling the valuation Enveda reported 12 months earlier. Founded in 2019 by Viswa Colluru, an early Recursion Pharmaceuticals employee, the startup looks for medicines in plants and microbes rather than synthesizing them from scratch. It is already testing candidates in patients for severe skin conditions and for maintaining weight loss after GLP-1 treatment, though no AI-discovered drug has FDA approval yet.
- Series E of $311 million values Enveda at $2 billion.
- Catalio Capital Management led, with Iconiq participating.
- Valuation doubled compared with 12 months earlier.
- Trials cover severe skin disease and post-GLP-1 weight maintenance.
Full article150 words · extracted from techcrunch.com · click to collapse
Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation. The fresh funding, which was led by Catalio Capital Management, with participation from Iconiq and others, doubles the valuation Enveda achieved 12 months ago.
The idea behind Enveda is that powerful medicines could be harnessed from plants and microbes, rather than synthesized from scratch in a lab. Viswa Colluru, an early employee of Recursion Pharmaceuticals, founded Enveda in 2019 to speed up the process of discovering these new drugs using AI and other techniques.
While AI hasn’t yet produced any FDA-approved drugs, Enveda is among the wave of companies advancing AI-discovered candidates into human clinical trials. The startup is currently testing several drugs in patients, including one targeting severe skin conditions and another designed to help maintain weight loss after stopping GLP-1s.
Text extracted automatically; images, tables and formatting may be missing. Original: https://techcrunch.com/2026/09/23/enveda-secures-311m-to-bring-more-nature-derived-ai-drugs-into-clinical-trials/